George Tziras

Small Pharma Inc. (OTCQB: DMTTF), a biotech company that develops short-acting psychedelic-assisted therapies for depression, received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Research Ethics Committee to begin a Phase 1 clinical study...

Short-acting psychedelics biotech firm Small Pharma Inc. (OTCQB: DMTTF) received a USPTO patent protecting the composition matter of a group of deuterated DMT compounds, with expected exclusivity until April 2041.  “We have made significant strides this year progressing our research...

Biotech producer of short-acting psychedelics for therapeutic purposes Small Pharma Inc. (OTCQB: DMTTF) has been granted a patent by the Canadian Intellectual Property Office as of July 19, 2022, which protects the composition of matter of specific deuterated DMT analogs including the active...

Biotech psychedelics company Small Pharma Inc. (OTCQB: DMTTF) has received an Issue Notification from the United States Patent and Trademark Office (USPTO) confirming that its patent application for novel injectable formulations of DMT-based compounds has been approved and will be granted as...

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras. Compass Pathways Adds Kabir Nath On Board Nath will effectively become chief executive officer...